NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $1.62 +0.02 (+1.25%) Closing price 04:00 PM EasternExtended Trading$1.62 -0.01 (-0.31%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cabaletta Bio Stock (NASDAQ:CABA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cabaletta Bio alerts:Sign Up Key Stats Today's Range$1.60▼$1.6750-Day Range$1.33▼$1.9952-Week Range$0.99▼$6.26Volume797,296 shsAverage Volume1.55 million shsMarket Capitalization$148.17 millionP/E RatioN/ADividend YieldN/APrice Target$14.43Consensus RatingBuy Company Overview Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Read More Cabaletta Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCABA MarketRank™: Cabaletta Bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 662nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 1 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.39% of the float of Cabaletta Bio has been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 7.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.39% of the float of Cabaletta Bio has been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 7.80%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 10 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by Insiders11.25% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Cabaletta Bio's insider trading history. Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Stock News HeadlinesWilliam Blair Sticks to Its Buy Rating for Cabaletta Bio (CABA)August 9, 2025 | theglobeandmail.comCabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis NearsAugust 9, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 22 at 2:00 AM | Porter & Company (Ad)Cabaletta Bio files $240M mixed securities shelfAugust 8, 2025 | msn.comCabaletta Bio (CABA) Q2 Loss Widens 30%August 7, 2025 | fool.comCabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comIndividual investors who have a significant stake must be disappointed along with institutions after Cabaletta Bio, Inc.'s (NASDAQ:CABA) market cap dropped by US$17mAugust 5, 2025 | finance.yahoo.comCabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus TreatmentJuly 21, 2025 | tipranks.comSee More Headlines CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $2.27 at the beginning of the year. Since then, CABA shares have decreased by 28.6% and is now trading at $1.62. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.02. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's top institutional shareholders include Bain Capital Life Sciences Investors LLC (19.07%), Adage Capital Partners GP L.L.C. (17.40%), Jennison Associates LLC (11.86%) and Jefferies Financial Group Inc. (3.94%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder and Catherine Bollard. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/07/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CABA CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Cabaletta Bio$14.43 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+787.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$115.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.11% Return on Assets-74.08% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.83Miscellaneous Outstanding Shares91,460,000Free Float81,175,000Market Cap$148.62 million OptionableOptionable Beta2.74 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CABA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.